| Date | Title | Description | Source |
| 30.04.2024 | I-MAB Filed 2023 Annual Report on Form 20-F | ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S... | en.prnasia... |
| 05.04.2024 | I-Mab to Participate at the 23rd Annual Needham Virtual Heal... | ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech com... | en.prnasia... |
| 03.04.2024 | I-Mab Announces Closing of the Divestiture of Business Opera... | ROCKVILLE, Md., April 3, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-... | en.prnasia... |
| 15.03.2024 | I-Mab Reports Full Year 2023 Financial Results and Business ... | Recently announced agreement to divest assets and business operations in China marks an important mi... | en.prnasia... |
| 07.02.2024 | I-Mab Signs Agreement to Divest its Assets and Business Oper... | Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotec... | en.prnasia... |
| 06.11.2023 | I-Mab Announces Participation at Jefferies and Piper Confere... | ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Com... | en.prnasia... |
| 02.11.2023 | Felzartamab Granted Breakthrough Therapy Designation by U.S.... | FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from... | en.prnasia... |
| 01.11.2023 | I-Mab Announces Poster Presentations of 4-1BB Bispecific Ant... | ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the &quo... | en.prnasia... |
| 16.10.2023 | I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 | ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Co... | en.prnasia... |
| 10.10.2023 | I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB... | - Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete respons... | en.prnasia... |
| 05.09.2023 | I-Mab Announces Upcoming Participation at September Conferen... | ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company&q... | en.prnasia... |
| 17.08.2023 | I-Mab Provides Mid-Year 2023 Financial Results, Business and... | Significant progress made year-to-date on key clinical assets:
‐ Uliledlimab (CD73 antibody): Encour... | en.prnasia... |
| 08.08.2023 | I-Mab to Report Mid-Year 2023 Financial Results, Business an... | ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: I... | en.prnasia... |
| 05.07.2023 | I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecifi... | GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 22.06.2023 | I-Mab Announces the Appointment of Raj Kannan as CEO | GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "... | en.prnasia... |
| 26.05.2023 | I-Mab Announces Encouraging Phase 1b/2 Study Results of Pati... | - Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger a... | en.prnasia... |
| 01.05.2023 | I-MAB Filed 2022 Annual Report on Form 20-F | GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Co... | en.prnasia... |
| 26.04.2023 | I-Mab Announces Poster Presentation of Proprietary CD73 Anti... | GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | en.prnasia... |
| 25.04.2023 | I-Mab Announces Positive Outcome in Arbitration Relating to ... | Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-ye... | en.prnasia... |
| 24.04.2023 | I-Mab Announces First Patient Dosed in Phase 3 Registrationa... | GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | en.prnasia... |
| 31.03.2023 | I-Mab Provides Business and Corporate Updates and Reports Fi... | Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall str... | en.prnasia... |
| 20.03.2023 | I-Mab to Report Full Year 2022 Financial Results and Provide... | GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company"... | en.prnasia... |
| 07.03.2023 | MSCI ESG Updated I-Mab to "A" Rating | GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 03.11.2022 | I-Mab Announces Two Poster Presentations of CD47 Antibody Le... | GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 13.09.2022 | I-Mab Announces Approval from China CDE to Initiate Phase 3 ... | GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | en.prnasia... |
| 10.09.2022 | I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Co... | Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients
For... | en.prnasia... |
| 30.08.2022 | I-Mab Provides Business and Corporate Updates and Reports Fi... | Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparli... | en.prnasia... |
| 23.08.2022 | I-Mab Announces Share Purchase Plans by the Company and the ... | GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "... | en.prnasia... |
| 19.08.2022 | I-Mab to Report Business and Corporate Updates and Financial... | - Major updates will focus on global clinical development of core assets, upcoming milestones and fi... | en.prnasia... |
| 18.07.2022 | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemz... | GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 06.07.2022 | I-Mab to Host 2022 R&D Day | GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "C... | en.prnasia... |
| 23.06.2022 | I-Mab Receives Top Rankings in Five Categories by Institutio... | GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "... | en.prnasia... |
| 15.06.2022 | I-Mab Partner MorphoSys Announces New License Agreements for... | SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 31.05.2022 | I-Mab Announces Completion of Patient Enrollment in Phase II... | SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 27.05.2022 | I-Mab Reports Latest Phase 2 Clinical Data of its Differenti... | - Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripa... | en.prnasia... |
| 19.05.2022 | I-Mab to Hold Investor Call to Report Latest Phase 2 Clinica... | SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 05.05.2022 | I-Mab Provides Updates on Status under Holding Foreign Compa... | SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Co... | en.prnasia... |
| 29.04.2022 | I-Mab Announces Appointments of Richard Yeh as Chief Operati... | - Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, globa... | en.prnasia... |
| 31.03.2022 | I-Mab Announces Voluntary Lock-ups by Key Shareholders and S... | SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | en.prnasia... |
| 29.03.2022 | I-Mab Provides Business and Corporate Updates and Reports Fi... | Financial results demonstrate strong fundamentals
Twenty key clinical milestones achieved year-to-da... | en.prnasia... |
| 18.03.2022 | I-Mab to Report Full Year 2021 Financial Results and Provide... | SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 15.03.2022 | I-Mab Provides Updates Regarding Holding Foreign Companies A... | SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the &quo... | en.prnasia... |
| 09.03.2022 | I-Mab Announces Multiple Presentations at the 2022 American ... | SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 03.03.2022 | I-Mab Receives FDA Orphan Drug Designation for its Novel Cla... | SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 28.01.2022 | I-Mab Announces Partnership Agreement to Localize Manufactur... | SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 28.01.2022 | I-Mab Announces Partnership Agreement to Localize Manufactur... | SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 28.01.2022 | I Mab : Announcement on Unusual Price Movement - Form 6-K | I-Mab's Announcement on Unusual Price Movement
SHANGHAI, China, and GAITHERSBURG, MD. -I-Mab (the &q... | marketscre... |
| 18.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Combina... | SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 18.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Combina... | SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 14.01.2022 | I-Mab Announces Execution of Senior Management Team Share Pu... | The execution demonstrates senior management team's tremendous confidence in the Company's innovativ... | en.prnasia... |
| 12.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Clinica... | SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 12.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Clinica... | SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 06.01.2022 | I-Mab Announces Senior Management Team Share Purchase Plan | SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 31.12.2021 | I-Mab Announces Upcoming Participation at January Conference... | SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 31.12.2021 | I-Mab Announces Upcoming Participation at January Conference... | SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 27.12.2021 | I-Mab Announces IND Approval from China NMPA for Phase 2 Cli... | SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 27.12.2021 | I-Mab Announces IND Approval from China NMPA for Phase 2 Cli... | SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 20.12.2021 | I-Mab Strengthens Management Team Designed to Accelerate Glo... | - New appointments as part of the Company's strategic development plans to accelerate transformation... | en.prnasia... |
| 15.12.2021 | I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bi... | SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 15.12.2021 | I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bi... | SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 09.12.2021 | I-Mab to Hold Investor Call to Present In-depth Clinical Dat... | SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 08.12.2021 | I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of... | SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | marketscre... |
| 08.12.2021 | I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of... | SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 07.12.2021 | I-Mab to Pursue Dual Listing Plan on The Main Board of The S... | SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 06.12.2021 | I Mab : Announces First Two Patients Dosed in U.S. Phase 2 C... | I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezo... | marketscre... |
| 03.12.2021 | I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Com... | SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 03.12.2021 | I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Com... | SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | marketscre... |
| 10.11.2021 | I-Mab and Jumpcan Announce Strategic Commercial Partnership ... | The partnership brings together the strengths of an innovative global biotech and a domestic leading... | en.prnasia... |
| 09.11.2021 | I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting... | Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanc... | en.prnasia... |
| 08.11.2021 | I-Mab and Roche Diagnostics Announce Strategic Collaboration... | SHANGHAI and GAITHERSBURG, Md., Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 04.11.2021 | I-Mab to Present Clinical Data of Lemzoparlimab in Combinati... | Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed i... | en.prnasia... |
| 03.11.2021 | I-Mab Announces Upcoming Participation at November Conferenc... | SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | marketscre... |
| 03.11.2021 | I-Mab Announces Upcoming Participation at November Conferenc... | SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 02.11.2021 | I-Mab Strengthens Senior Executive Team with New Chief Finan... | I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy
Officer ... | marketscre... |
| 01.11.2021 | I-Mab Strengthens Senior Executive Team with New Chief Finan... | SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 01.11.2021 | I-Mab Strengthens Senior Executive Team with New Chief Finan... | - Industry veteran John Long appointed as CFO to lead I-Mab's global corporate finance and capital m... | marketscre... |
| 26.10.2021 | I-Mab Announces Strategic Partnership with Sinopharm in Prep... | I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, incl... | en.prnasia... |
| 26.10.2021 | I-Mab Announces Strategic Partnership with Sinopharm in Prep... | I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, incl... | marketscre... |
| 22.10.2021 | I-Mab : Expands U.S. Footprint with New R&D Site in San ... | - I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational ... | marketscre... |
| 22.10.2021 | I-Mab Expands U.S. Footprint with New R&D Site in San Di... | - I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational ... | en.prnasia... |
| 19.10.2021 | I Mab : Announces IND Approval for Phase 2 Clinical Trial of... | I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1... | marketscre... |
| 18.10.2021 | I-Mab : Announces IND Approval for Phase 2 Clinical Trial of... | SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 18.10.2021 | I-Mab Announces IND Approval for Phase 2 Clinical Trial of E... | SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 13.10.2021 | I-Mab Advances Late-stage Development of Its Differentiated ... | Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lena... | en.prnasia... |
| 01.10.2021 | I-Mab : Announces Upcoming Participation at October Conferen... | SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | marketscre... |
| 01.10.2021 | I-Mab Announces Upcoming Participation at October Conference... | SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq... | en.prnasia... |
| 30.09.2021 | I-Mab Reports Multiple Positive Clinical Updates of Differen... | The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for p... | en.prnasia... |
| 28.09.2021 | I-Mab : Announces Acceptance of IND Application from China N... | SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | marketscre... |
| 28.09.2021 | I-Mab Announces Acceptance of IND Application from China NMP... | SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | en.prnasia... |
| 13.09.2021 | I-Mab Added to FTSE ESG Index Series | SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | en.prnasia... |
| 13.09.2021 | I-Mab Added to FTSE ESG Index Series | | prnewswire... |
| 13.09.2021 | I-Mab : Added to FTSE ESG Index Series | SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasd... | marketscre... |
| 02.09.2021 | I-Mab Added to FTSE Russell Global Equity Index Series | SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 31.08.2021 | I-Mab Provides Business and Corporate Updates and Reports Fi... | 13 significant clinical milestones achieved year-to-date, including critical positive data readout e... | en.prnasia... |
| 30.08.2021 | I-Mab Announces Upcoming Participation at September Conferen... | | prnewswire... |
| 30.08.2021 | I-Mab Announces Upcoming Participation at September Conferen... | SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | en.prnasia... |
| 30.08.2021 | I-Mab : Announces Upcoming Participation at September Confer... | SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasda... | marketscre... |
| 20.08.2021 | I Mab : Announces Establishment of Environmental, Social and... | I-Mab Announces Establishment of Environmental, Social and Governance Committee
• I-Mab received hig... | marketscre... |
| 19.08.2021 | I-Mab : Announces Establishment of Environmental, Social and... | I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI
New major... | marketscre... |
| 19.08.2021 | I-Mab Announces Establishment of Environmental, Social and G... | I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI
New major... | en.prnasia... |
